ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across the globe and maintains offices, R&D centers, and production bases in 12 different cities within the United States, Switzerland, England, Germany, and China. ACROBiosystems Group has established numerous long-term and stable partnerships with the world’s top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises of several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics.ACROBiosystems’ brands include FLAG, Star Staining, ViruStop, Aneuro, ComboX, GENPower, and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics.Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and its clinical applications, and contributes to global health.

bioSeedin is a subsidiary of ACROBiosystems Inc. and ACROBiosystems Co. Ltd. (SHE: 301080), a biotechnology company focused on researching, developing, acquiring, and commercializing novel pharmaceutical and biotechnology products.bioSeedin, one of the most preeminent asset management, public relations, and financial advisory firms for biotech and pharmaceutical companies in APAC, operates across North America, Europe, and Asia. Based on hosting the annual Biopharmaceutical Developer Innovation Conference, the largest and most influential conference in Asia, bioSeedin aggregates industrial resources across 5000 pharmaceutical enterprises worldwide. The firm provides asset management services via licensing in and out, co-developmental partner sourcing, and project implementation, as well as advising on public relation management, Asia market entry, investment strategy, mergers and acquisitions, and capital raising.bioSeedin aims to be the supreme asset transaction platform for our global clients. By facilitating R&D efficiency, maximizing research resources and funding, and emerging market access to deliver therapeutics faster and benefit our patients worldwide.

•Initiated Manufacture Team associates to efficiently support low inventory refill recombinant protein production on tight schedule and manage inventory of finished bulks and reagents•Supported upstream production by maintaining 293E and CHO cells, routine transfection, and assignment of project to associate for purification•Supported optimization efforts by evaluating new ideas or technology that improved expression, purification of recombinants, scaled-up yield, or reduced time and cost of production•Analyzed experimental data and presented findings at department meetings, contributing to the advancement of project objectives•Responsible for operating multiple company ERP software to support new product release efforts, initiate bottling work orders, and input of all finished bulks into system•Responsible for fulfilling custom order specification protein production service requests, preparing documentation, reviewing specifications before transfer of final product to customer•Participated in hiring process for new associates, provided supervision, training and performance reviews•Created, revised, and provided training for technical standard operating procedures

•Supported new product development by successfully cloning an average of 120 new recombinant constructs per year for proteins of interest from PCR to DNA sequencing analysis•Determined best host for expression of new constructs in 293E, CHO, or E. coli expression systems using small scale expression assessments•Developed on average 10-12 new catalog recombinant proteins per year to support new product release•Developed production protocols for E. coli expressed recombinants from cell culture, soluble or inclusion body expression, refolding, to protein purification by FPLC/non-automated methods, and endotoxin removal•Developed production protocols for mammalian expressed recombinants from cell culture, transfection to protein purification by FPLC/non-automated methods, and endotoxin removal•Troubleshooted production problems concerning cell culture, protein expression, refolding, purification, or bioactivity•Supported team with training for new associates, large-scale buffer preparation, ordering low-inventory chemicals and reagents, and lab equipment maintenance•Operated under ISO9001, ISO13845, BSL2 laboratory practices